August 30, 2024

J&J targets generalised myasthenia gravis landscape with nipocalimab – Pharmaceutical Technology

August 29, 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis – PR Newswire

August 29, 2024

PRIME® Online Activity – FcRn Antagonists: Transformative Potential in Treating Generalized Myasthenia Gravis – PRIME® Continuing Medical Education

August 29, 2024

Personalized Pathways for Managing Generalized Myasthenia Gravis: The Role of FcRn Antagonism – PRIME® Continuing Medical Education

August 26, 2024

Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study – Frontiers